Monitoring the effect of chemotherapy in a mixed glioma by C-11-methionine PET

Journal of Neuroimaging

Volumn 13, Issue 3, 2003, Pages 269-271

  Herholz, K ^a   Kracht, L W ^b   Heiss, W D ^b  

^a MAX PLANCK INSTITUTE FOR NEUROLOGICAL RESEARCH   (Germany)

^b NONE

Author keywords

C 11 methionine; Chemotherapy; Glioma; Oligodendroglioma; Positron emission tomography; Procarbazine; Treatment monitoring

Indexed keywords

ANTINEOPLASTIC AGENT; LOMUSTINE; METHIONINE C 11; NIMUSTINE; PROCARBAZINE; VINCRISTINE;

ADULT; ALEXIA; ARTICLE; ASTROCYTOMA; CANCER REGRESSION; CANCER SURGERY; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DISEASE COURSE; DRUG EFFICACY; DRUG MONITORING; FEMALE; FOLLOW UP; GLIOMA; GRAND MAL SEIZURE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMAGE ANALYSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; TREATMENT INDICATION; TREATMENT OUTCOME; TUMOR VOLUME; VISUAL HALLUCINATION;

ADULT; ASTROCYTOMA; BRAIN NEOPLASMS; CEREBRAL CORTEX; CHEMOTHERAPY, ADJUVANT; DRUG MONITORING; FEMALE; HUMANS; METHIONINE; RADIOPHARMACEUTICALS; TOMOGRAPHY, EMISSION-COMPUTED; TREATMENT OUTCOME;

EID: 0038798593     PISSN: 10512284     EISSN: None     Source Type: Journal    
DOI: 10.1177/1051228403013003012     Document Type: Article

References (23)

1. Mason W, Louis DN, Cairncross JG. Chemosensitive gliomas in adults: which ones and why? J Clin Oncol 1997;15(12):3423-3426.
2. Smith JS, Perry A, Borell TJ, et al. Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol 2000;18(3):636.
3. Burton EC, Prados MD. Malignant gliomas. Curr Treat Options Oncol 2000;1(5):459-468.
4. Grant R, Liang BC, Slattery J, Greenberg HS, Junck L. Chemotherapy response criteria in malignant glioma. Neurology 1997;48(5):1336-1340.
5. Levivier M, Becerra A, De Witte O, Brotchi J, Goldman S. Radiation necrosis or recurrence. J Neurosurg 1996;84(1):148-149.
6. Cairncross JG, Macdonald DR, Pexman JH, Ives FJ. Steroid-induced CT changes in patients with recurrent malignant glioma. Neurology 1988;38(5):724-726.
7. Ostergaard L, Hochberg FH, Rabinov JD, et al. Early changes measured by magnetic resonance imaging in cerebral blood flow, blood volume, and blood-brain barrier permeability following dexamethasone treatment in patients with brain tumors. J Neurosurg 1999;90(2):300-305.
8. Nuutinen J, Sonninen P, Lehikoinen P, et al. Radiotherapy treatment planning and long-term follow-up with [(11)C]methionine PET in patients with low-grade astrocytoma. Int J Radiat Oncol Biol Phys 2000;48(1):43-52.
9. Würker M, Herholz K, Voges J, et al. Glucose consumption and methionine uptake in low-grade gliomas after iodine-125 brachytherapy. Eur J Nucl Med 1996;23(5):583-586.
10. Voges J, Herholz K, Holzer T, et al. 11C-methionine and 18F-2-fluorodeoxyglucose positron emission tomography: a tool for diagnosis of cerebral glioma and monitoring after brachytherapy with 1251 seeds. Stereotact Funct Neurosurg 1997;69(1-4 Pt 2):129-135.
11. Shintani S, Tsuruoka S, Shiigai T. Serial positron emission tomography (PET) in gliomatosis cerebri treated with radiotherapy: a case report. J Neurol Sci 2000;173(1):25-31.
12. Mosskin M, Ericson K, Hindmarsh T, et al. Positron emission tomography compared with magnetic resonance imaging and computed tomography in supratentorial gliomas using multiple stereotactic biopsies as reference. Acta Radiologica 1989;30(3):225-232.
13. Herholz K, Hölzer T, Bauer B, et al. 11C-methionine PET for differential diagnosis of low-grade gliomas. Neurology 1998;50(5):1316-1322.
14. Sonoda Y, Kumabe T, Takahashi T, Shirane R, Yoshimoto T. Clinical usefulness of 11C-MET PET and 201T1 SPECT for differentiation of recurrent glioma from radiation necrosis. Neurol Med Chir (Tokyo) 1998;38(6):342-347.
15. Goldman S, Levivier M, Pirotte B, et al. Regional methionine and glucose uptake in high-grade gliomas: a comparative study on PET-guided stereotactic biopsy. J Nucl Med 1997;38(9):1459-1462.
16. Bustany P, Chatel M, Derlon JM, et al. Brain tumor protein synthesis and histological grades: a study by positron emission tomography (PET) with C11-L-methionine. J Neurooncol 1986;3(4):397-404.
17. Rozental JM, Levine RL, Mehta MP, et al. Early changes in tumor metabolism after treatment: the effects of stereotactic radiotherapy. Int J Radiat Oncol Biol Phys 1991;20(5):1053-1060.
18. Brock CS, Young H, O'Reilly SM, et al. Early evaluation of tumour metabolic response using [18F]fluorodeoxyglucose and positron emission tomography: a pilot study following the phase II chemotherapy schedule for temozolomide in recurrent high-grade gliomas. Br J Cancer 2000;82(3):608-615.
19. Kaschten B, Stevenaert A, Sadzot B, et al. Preoperative evaluation of 54 gliomas by PET with fluorine-18-fluorodeoxyglucose and/or carbon-11-methionine. J Nucl Med 1998;39(5):778-785.
20. Roesdi MF, Postma TJ, Hoekstra OS, van Groeningen CJ, Wolbers JG, Heimans JJ. Thallium-201 SPECT as response parameter for PCV chemotherapy in recurrent glioma. J Neurooncol 1998;40(3):251-255.
21. Schwartz RB, Holman BL, Polak JF, et al. Dual-isotope single-photon emission computerized tomography scanning in patients with glioblastoma multiforme: association with patient survival and histopathological characteristics of tumor after high-dose radiotherapy. J Neurosurg 1998;89(1):60-68.
22. Langen KJ, Ziemons K, Kiwit JC, et al. 3-[123I]iodo-alpha-methyltyrosine and [methyl-11C]-L-methionine uptake in cerebral gliomas: a comparative study using SPECT and PET. J Nucl Med 1997;38(4):517-522.
23. Preul MC, Caramanos Z, Villemure JG, et al. Using proton magnetic resonance spectroscopic imaging to predict in vivo the response of recurrent malignant gliomas to tamoxifen chemotherapy. Neurosurgery 2000;46(2):306-318.